Switching of antipsychotics to aripiprazole in the treatment of schizophrenia

Chang Gung Medical Journal

Volumn 32, Issue 4, 2009, Pages 409-416

  Lin, Huang Chi ^a   Chong, Mian Yoon ^a   Lee, Yu ^a   Yeh, Wei Chiang ^a   Lin, Pao Yen ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Antipsychotics; Aripiprazole; Drug switching; Schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SULPIRIDE; TRIFLUOPERPRAZINE; UNCLASSIFIED DRUG; ZIPRASIDONE;

ADULT; AKATHISIA; ANXIETY; ARTICLE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; GALACTORRHEA; HAND TREMOR; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERPROLACTINEMIA; INSOMNIA; MALE; MICTURITION DISORDER; OBSERVATIONAL STUDY; PARKINSONISM; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SIDE EFFECT; TACHYCARDIA; WEIGHT GAIN; XEROSTOMIA;

ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; QUINOLONES; SCHIZOPHRENIA;

EID: 70349165532     PISSN: 20720939     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Jobe TH, Harrow M. Long-term outcome of patients with schizophrenia: a review. Can J Psychiatry 2005;50:892-900. (Pubitemid 43161743)
2. Jibson MD, Tandon R. New atypical antipsychotic medications. J Psychiatr Res 1998;32:215-228
3. Davis JM, Chen N. Clinical profile of an atypical antipsychotic: risperidone. Schizophr Bull 2002;28:43-61. (Pubitemid 34534749)
4. Davis JM, Chen N. The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and international trials. J Clin Psychiatry 2001;62:757-771 (Pubitemid 33104662)
5. Karow A, Naber D. Subjective well-being and quality of life under atypical antipsychotic treatment. Psychopharmacology 2002;162:3-10. (Pubitemid 34639549)
6. Chong MY, Tan CH, Fujii S, Yang SY, Ungvari GS, Si T, Chung EK, Sim K, Tsang HY, Shinfuku N. Antipsychotic drug prescription for schizophrenia in East Asia: rationale for change. Psychiatry Clin Neurosci 2004;58:61-67 (Pubitemid 38200373)
7. Burns T, Chabannes JP, Demyttenaere K. Switching antipsychotic medications: general recommendations and switching to amisulpride. Curr Med Res Opin 2002;18:201-208 (Pubitemid 34886823)
8. Ganguli R. Rationale and strategies for switching antipsychotics. Am J Health Syst Pharm 2002;59:S22-6.
9. Masand PS. A review of pharmacologic strategies for switching to atypical antipsychotics. Prim Care Companion J Clin Psychiatry 2005;7:121-129 (Pubitemid 41783228)
10. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 2007;68 Supp 1:20-27
11. Swainston HT, Perry CM. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs 2004;64:1715-1736 (Pubitemid 39128008)
12. Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, Stringfellow J, Ingenito G, Marder SR. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003;60:681-690 (Pubitemid 36818630)
13. Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002;63:763-771
14. Pigott TA, Carson WH, Saha AR, Torbeyns AF, Stock EG, Ingenito GG. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003;64:1048-1056
15. Weiden PJ, Miller AL, Lambert TJ, Buckley PF. The art and science of switching antipsychotic medications, part 2. J Clin Psychiatry 2007;68:e02.
16. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994:147-151
17. Guy Y. ECDEU Assessment Manual for Psychopharmacology. U.S Department of Health, Education and Welfare, DHEW publication: Rockville, Md, 1976:218-222
18. Chang WH. Selection of antipsychotics for the treatment of schizophrenia. Taiwanese J Psychiatry 2005;19:264-282
19. WHO Collaborating Center for Drug Statistic Methodology. ATC index with DDDs. WHO Collaborating Center for Drug Statistics Methodology. Oslo Norway: WHO, 2007.
20. Stahl SM. Essential Psychopharmacology. Antipsychotic Agents: Neuroscientif-ic Basis and Practical Applications. Cambridge, United Kingdom: Cambridge University Press, 2000:401-458
21. Reynolds GP, Templeman LA, Godlewska BR. Pharmacogenetics of schizophrenia. Expert Opin Pharmacother 2006;7:1429-1440
22. Casey DE. Metabolic issues and cardiovascular disease in patients with psychiatric disorders. Am J Med 2005;118 Suppl 2:15S-22S.
23. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, Roth BL, Mailman R. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003;28:1400-1411 (Pubitemid 41070874)
24. Chan HY, Lin WW, Lin SK, Hwang TJ, Su TP, Chiang SC, Hwu HG. Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial. J Clin Psychiatry 2007;68:29-36. (Pubitemid 46220121)
25. Sadock BJ, Sadock VA. Synopsis of Psychiatry. Biological Therapies. 9th ed. Philadelphia, USA: Lippincott, Williams & Wilkins, 2003:974-1144.
26. Casey DE, Carson WH, Saha AR, Liebeskind A, Ali MW, Jody D, Ingenito GG. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology 2003;166:391-399 (Pubitemid 36469941)
27. Chouinard G. Severe cases of neuroleptic-induced supersensitivity psychosis: Diagnostic criteria for the disorder and its treatment. Schizophr Res 1991;5:21-33.
28. Szymanski SR, Cannon TD, Gallacher F, Erwin RJ, Gur RE. Course of treatment response in first-episode and chronic schizophrenia. Am J Psychiatry 1996;153:519-525 (Pubitemid 26113316)
29. Kapur S, Seeman P. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 2001;158:360-369 (Pubitemid 32205190)
30. Seeman P, Tallerico T. Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am J Psychiatry 1999;156:876-884 (Pubitemid 29260342)
31. Verghese C, DeLeon J, Nair C, Simpson GM. Clozapine withdrawal effects and receptor profiles of typical and atypical neuroleptics. Biol Psychiatry 1996;39:135-138 (Pubitemid 26045301)
32. Remington G, Chue P, Stip E, Kopala L, Girard T, Christensen B. The crossover approach to switching antipsychotics: what is the evidence? Schizophr Res 2005;76:267-272
33. Weiden PJ, Buckley PF. Reducing the burden of side effects during long-term antipsychotic therapy: the role of "switching" medications. J Clin Psychiatry. 2007;68 Suppl 6:14-23.